AsianFin -- The start of 2025 has witnessed a significant milestone in the global licensing agreements for innovative drugs. On January 2, Innovent Biologics announced it had signed an exclusive global licensing agreement with Roche for its antibody-drug conjugate (ADC) IBI3009. The agreement includes an upfront payment of $80 million, potential milestone payments of up to $1 billion, and future royalties based on sales.
Looking back at 2024, Chinese pharmaceutical companies such as HengRui Medicine, LianXin Pharmaceutical, and YingEn Biotech successfully introduced their products to international markets, showcasing a blooming presence globally. Additionally, the approval rate for new drugs and the proportion of domestically produced medicines reached historic highs.
Industry insiders highlighted that “expansion overseas” and “innovation” have become key themes in the pharmaceutical industry. With continuous policy support driving innovation and comprehensive top-down and local-level policies fostering the development of innovative drugs, the R&D capabilities of Chinese pharmaceutical companies have significantly strengthened. The overseas market has provided a vast platform for the growth of domestic innovative drugs, signaling an upward trend for the industry as a whole.
Explore more exclusive insights at nextfin.ai.
